Endocrine Abstracts

Low testosterone is associated with an increased prevalence of cardiovascular (CV) disease. Testosterone replacement improves several CV risk factors including lowering cholesterol and may protect against atherogenesis. Macrophage liver X receptor α (LXRα) stimulates cholesterol efflux which is a therapeutic target for the treatment of atherosclerosis. It was therefore proposed that the anti-atherogenic effect of testosterone may be mediated via LXRα. THP-1 macr...

Low testosterone is associated with an increased prevalence of cardiovascular (CV) diseases such as atherosclerosis. Testosterone replacement improves several CV risk factors including lowering cholesterol. Liver X receptor α (LXRα) is present in various cell types such as macrophages where it stimulates cholesterol efflux and this ability means LXRα agonists are a potential therapy for atherosclerosis. It was therefore proposed that testosterone acts to reduce ...

Introduction: Bile acid malabsorption (BAM) may be a contributing factor causing diarrhoea in patients with NETs, particularly among those who have undergone previous surgical resection of the terminal ileum and/or right colon or cholecystectomy (Naraev et al 2019). Aim(s): To identify the prevalence of bile acid malabsorption in neuroendocrine tumour patients (NET) at the Queen Elizabeth Hospital Birmingham (QEHB). Materi...

Background: In the UK, adults with growth hormone deficiency (GHD) are treated with recombinant Growth Hormone (GH) therapy according to NICE guidelines (TA64). Provided that patients show an initial improvement in their quality-of-life score, assessed using the Quality-of-Life Assessment of GHD in Adults (Qol-AGHDA) questionnaire, they can continue with their GH treatment long-term. However, in clinical practice, many patients are observed to discontinue GH r...

Adult growth hormone deficiency (AGHD) is a metabolic syndrome characterised by osteoporosis, increased visceral fat, adverse lipid profiles, decreased muscle mass and reduced energy levels. As such, it is associated with reduced quality of life (QoL) and increased mortality from cardiovascular disease. Synthetic growth hormone (GH) can be given to replace natural GH; however, treatment is costly at around £3350 per patient per year and could cause side effects including ...

Androgen deprivation therapy (ADT) when used in the treatment of prostate carcinoma produces a severe state of hypogonadism. Several but not all epidemiological studies have reported that there is an increased incidence of cardiovascular disease (CVD) including myocardial infarction, life threatening arrhythmias, diabetes and sudden cardiac death (1). Studies have also shown that ADT causes adverse effects many within three months on several key cardiovascular risk factors. Th...

Background: Radioiodine therapy (I-131) is commonly prescribed for benign thyroid disease in keeping with recommended guidelines.Aims: To determine the effectiveness of I-131 in treating benign thyroid disease and the rates of hypothyroidism following treatment and by diagnosis.Methods: We identified 100 patients who received radioiodine therapy between November 2013 and June 2015 from a database held in the Medical Physics Departm...

Male hypogonadism can occur either due to disorders at the hypothalamic or pituitary levels or as a result of primary testicular failure. Conventionally, testosterone is replaced by depot intramuscular injections of testoterone esters or as implants producing non-physiological levels of serum testosterone. Human chorionic gonadotrophin (hCG) given twice-weekly s.c., stimulates endogenous testosterone secretion through its LH like action resulting in physiological serum testost...

Objectives: Symptomatic hypogonadism is common in obese men with type-2 diabetes (T2DM) and metabolic syndrome (MetS), and is now an independent risk factor for cardiovascular disease. Testosterone replacement therapy (TRT) improves cholesterol metabolism in hypogonadal men with T2DM and/or MetS. We have previously shown that a non-functional androgen receptor (AR) and low levels of circulating testosterone in the testicular feminised (Tfm) mouse is associated with elevated ch...

VA Thornton-Jones, JAH Wass and HE Turner, OBJECTIVE: Despite a recommended injection frequency of 4 weekly(4w), prolonged duration of GH suppression has been observed in some patients following treatment with long-acting somatostatin analogues. The aim of our study was to perform a prospective systematic study to determine whether extending the interval between doses of Octreotide LAR (LAR) allows maintenance of 'safe' GH in selected patients with acromegaly.<p class="abs...